Simply Wall St.1d agoneutral
Iovance Biotherapeutics (IOVA) Q3 Earnings Sharpen Focus On Margin RecoveryNews
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
106last 24h
3125last 7d
511● bullish (7d)
311● bearish (7d)
227publishers
GuruFocus.com2d agoneutral
Iovance Biotherapeutics Inc (IOVA) (Q3 2026) Earnings Call Highlights: Record $122 Million ...MT Newswires5d agoneutral
UBS Adjusts Price Target on Iovance Biotherapeutics to $8 From $7, Maintains Neutral RatingSimply Wall St.9d agoneutral
Iovance Biotherapeutics (IOVA) Posts 59.1% Response In Lifileucel Lung Cancer StudyStocktwits40d agoneutral
IOVA Stock Hits Over 2-Year Highs - Why Iovance Raised Its FY2026 Revenue OutlookSimply Wall St.50d agoneutral
Iovance Biotherapeutics (IOVA) Is Up 19.2% After Record Q2 Amtagvi Revenue And TIL Pipeline ExpansionSimply Wall St.50d agoneutral
Iovance Biotherapeutics (IOVA) Stock Fair Value Edges Higher On Amtagvi Margin ProgressMarketBeat50d agoneutral
Iovance Maps TIL Therapy Expansion After Record Revenue and Margin Gains